Sarah Richman, MD, PhD News

Chimeric antigen receptor (CAR) T-cell therapy uses a person’s own immune cells that have been modified to recognize and attack cancer cells.

Dramatic advances in cancer research and treatment over the past two decades have made it possible for more children to survive a cancer diagnosis.

Children’s Hospital Los Angeles annual research symposium events focused on the role of nutrition and other factors in childhood and lifetime health.

Four investigators share their research—and how the USC/CHLA facility will help bring novel cell therapies to clinical trials faster.

In the News - Awards and Honors - New Faces

Sarah Richman, MD, PhD Cancer and Blood Disease Institute Sarah Richman, MD, PhD, investigates the use of chimeric antigen receptor (CAR) T-cell therapy for solid tumors. She and others in the field

With the addition of four scientists, the team is developing new and innovative approaches to CAR-T therapy in children.